A completed clinical trial of PYR as a STAT3 inhibitor in chronic lymphocytic leukemia reported in vivo efficacy of STAT3 suppression, overall safety, and stable disease for 50% of the patients (NCT01066663) [23]. The gene discussed is STAT3; the disease is B-cell chronic lymphocytic leukemia.